Cytokinetics looks beyond reldesemtiv miss in ALS

Cytokinetics signaled its interest in continuing reldesemtiv’s development for ALS even as the candidate failed to meet the primary and secondary endpoints in the Phase II FORTITUDE-ALS trial to treat amyotrophic lateral sclerosis.

"We went into this trial sober to the reality that if these data aren't compelling,

Read the full 478 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE